Trial: 202005130

A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line, Metastatic KEAP1/NRF2-mutated Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)

Phase

II (Cancer Control)

Principal Investigator

Govindan, Ramaswamy

Disease Site

Lung; Lung Cancer – Non-small Cell

Learn more about this study at: clinicaltrials.gov